A Case of Duodenal Neuroendocrine Carcinoma Treated with Amrubicin as Second-line Chemotherapy

Authors

  • Tadahisa Inoue Department of Gastroenterology, Gifu Prefectural Tajimi Hospital, Tajimi, Japan
  • Hitoshi Sano Department of Gastroenterology, Gifu Prefectural Tajimi Hospital, Tajimi, Japan
  • Takashi Mizushima Department of Gastroenterology, Gifu Prefectural Tajimi Hospital, Tajimi, Japan
  • Hirotada Nishie Department of Gastroenterology, Gifu Prefectural Tajimi Hospital, Tajimi, Japan
  • Hiroyasu Iwasaki Department of Gastroenterology, Gifu Prefectural Tajimi Hospital, Tajimi, Japan
  • Fumihiro Okumura Department of Gastroenterology, Gifu Prefectural Tajimi Hospital, Tajimi, Japan

DOI:

https://doi.org/10.15403/jgld.2014.1121.243.ino

Keywords:

duodenal neuroendocrine carcinoma, amrubicin, chemotherapy

Abstract

We present the case of a Japanese man in his 60s with duodenal neuroendocrine carcinoma with distant metastases. Chemotherapy with irinotecan plus cisplatin was initiated as a first-line regimen. However, disease progression was observed after only two cycles. Therefore, amrubicin was administered as a second-line chemotherapy. The patient showed a long-term effect of amrubicin therapy, and the best response was a partial response after seven cycles. For duodenal neuroendocrine carcinoma, amrubicin therapy can be considered an effective treatment option as salvage chemotherapy.

Downloads

Published

2015-09-01

How to Cite

1.
Inoue T, Sano H, Mizushima T, Nishie H, Iwasaki H, Okumura F. A Case of Duodenal Neuroendocrine Carcinoma Treated with Amrubicin as Second-line Chemotherapy. JGLD [Internet]. 2015 Sep. 1 [cited 2025 Jul. 9];24(3):379-82. Available from: https://www.jgld.ro/jgld/index.php/jgld/article/view/1195

Issue

Vol. 24 No. 3: September 2015

Section

Case Reports